OptimizeRx
- Home ›
- US ›
- Healthcare
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The last earnings update was 39 days ago. More info.
Add to Portfolio Compare Print
- OptimizeRx has significant price volatility in the past 3 months.
OPRX Share Price and Events
7 Day Returns
1 Year Returns
OPRX Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| OptimizeRx (OPRX) | 8.2% | -8.8% | -3.1% | 78.3% | 340.1% | 200.8% |
| US Healthcare Services | 0.6% | 4.2% | 14.7% | 24.3% | 77.5% | 66% |
| US Market | 0.5% | 0.2% | 1.1% | 0.8% | 37.4% | 37.5% |
1 Year Return vs Industry and Market
- OPRX outperformed the Healthcare Services industry which returned 24.3% over the past year.
- OPRX outperformed the Market in United States of America which returned 0.8% over the past year.
OPRX Value
Is OptimizeRx undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
OptimizeRx
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for OptimizeRx.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 4 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 9.1% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Healthcare Services Unlevered Beta | Simply Wall St/ S&P Global | 1.11 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.108 (1 + (1- 21%) (0.33%)) |
1.074 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.07 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.074 * 5.96%) |
9.13% |
Discounted Cash Flow Calculation for NasdaqCM:OPRX using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for OptimizeRx is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 9.13%) |
|
|---|---|---|---|
| 2019 | 1.79 | Analyst x1 | 1.64 |
| 2020 | 8.82 | Analyst x2 | 7.40 |
| 2021 | 14.92 | Est @ 69.23% | 11.48 |
| 2022 | 22.27 | Est @ 49.28% | 15.70 |
| 2023 | 30.14 | Est @ 35.32% | 19.47 |
| 2024 | 37.84 | Est @ 25.54% | 22.40 |
| 2025 | 44.91 | Est @ 18.7% | 24.36 |
| 2026 | 51.16 | Est @ 13.91% | 25.43 |
| 2027 | 56.55 | Est @ 10.55% | 25.76 |
| 2028 | 61.20 | Est @ 8.21% | 25.54 |
| Present value of next 10 years cash flows | $179.17 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $61.20 × (1 + 2.73%) ÷ (9.13% – 2.73%) |
$981.98 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $981.98 ÷ (1 + 9.13%)10 |
$409.81 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $179.17 + $409.81 |
$588.98 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $588.98 / 13.82 |
$42.63 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $42.63 |
| Current discount | Discount to share price of
$14.26
= -1 x ($14.26 - $42.63) / $42.63 |
66.5% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- OptimizeRx's share price is below the future cash flow value, and at a moderate discount (> 20%).
- OptimizeRx's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for OptimizeRx's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
OptimizeRx's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $0.04 |
| NasdaqCM:OPRX Share Price ** | NasdaqCM (2019-06-14) in USD | $14.26 |
| United States of America Healthcare Services Industry PE Ratio | Median Figure of 13 Publicly-Listed Healthcare Services Companies | 52.35x |
| United States of America Market PE Ratio | Median Figure of 3,091 Publicly-Listed Companies | 17.68x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of OptimizeRx.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqCM:OPRX Share Price ÷ EPS (both in USD) = 14.26 ÷ 0.04 |
385.35x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- OptimizeRx is overvalued based on earnings compared to the US Healthcare Services industry average.
- OptimizeRx is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does
OptimizeRx's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 385.35x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts |
98.1%per year |
| United States of America Healthcare Services Industry PEG Ratio | Median Figure of 12 Publicly-Listed Healthcare Services Companies | 2.42x |
| United States of America Market PEG Ratio | Median Figure of 2,125 Publicly-Listed Companies | 1.52x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 385.35x ÷ 98.1% |
3.93x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- OptimizeRx is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
OptimizeRx's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $1.58 |
| NasdaqCM:OPRX Share Price * | NasdaqCM (2019-06-14) in USD | $14.26 |
| United States of America Healthcare Services Industry PB Ratio | Median Figure of 36 Publicly-Listed Healthcare Services Companies | 5.06x |
| United States of America Market PB Ratio | Median Figure of 5,244 Publicly-Listed Companies | 1.79x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqCM:OPRX Share Price ÷ Book Value per Share (both in USD) = 14.26 ÷ 1.58 |
9.01x |
* Primary Listing of OptimizeRx.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- OptimizeRx is overvalued based on assets compared to the US Healthcare Services industry average.
Value checks
We assess OptimizeRx's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check) OptimizeRx has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
OPRX Future Performance
How is OptimizeRx expected to perform in the next 1 to 3 years based on estimates from 4 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- OptimizeRx's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- OptimizeRx's earnings growth is expected to exceed the United States of America market average.
- OptimizeRx's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqCM:OPRX Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts | 98.1% |
| NasdaqCM:OPRX Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts | 27.2% |
| United States of America Healthcare Services Industry Earnings Growth Rate | Market Cap Weighted Average | 23.8% |
| United States of America Healthcare Services Industry Revenue Growth Rate | Market Cap Weighted Average | 11.8% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.9% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 4 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2020-12-31 | 36 | 6 | 4 | 3 |
| 2019-12-31 | 28 | 4 | 2 | 4 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 22 | 2 | 0 |
| 2018-12-31 | 21 | 1 | 0 |
| 2018-09-30 | 19 | 0 | 0 |
| 2018-06-30 | 16 | -2 | -1 |
| 2018-03-31 | 14 | -2 | -1 |
| 2017-12-31 | 12 | -1 | -2 |
| 2017-09-30 | 10 | -2 | -2 |
| 2017-06-30 | 9 | -1 | -2 |
| 2017-03-31 | 8 | 0 | -2 |
| 2016-12-31 | 8 | 0 | -2 |
| 2016-09-30 | 7 | 0 | -2 |
| 2016-06-30 | 8 | 0 | -1 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 4 Analyst Estimates (S&P Global) | See Below |
All data from OptimizeRx Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2020-12-31 | 0.32 | 0.47 | 0.16 | 2.00 |
| 2019-12-31 | 0.15 | 0.23 | 0.10 | 3.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | 0.04 |
| 2018-12-31 | 0.02 |
| 2018-09-30 | 0.01 |
| 2018-06-30 | -0.08 |
| 2018-03-31 | -0.14 |
| 2017-12-31 | -0.21 |
| 2017-09-30 | -0.22 |
| 2017-06-30 | -0.18 |
| 2017-03-31 | -0.21 |
| 2016-12-31 | -0.16 |
| 2016-09-30 | -0.16 |
| 2016-06-30 | -0.14 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if OptimizeRx will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess OptimizeRx's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
OptimizeRx has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
OPRX Past Performance
How has OptimizeRx performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- OptimizeRx's year on year earnings growth rate has been positive over the past 5 years.
- OptimizeRx has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
- OptimizeRx has become profitable in the last year making it difficult to compare the US Healthcare Services industry average.
Earnings and Revenue History
All data from OptimizeRx Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 22.30 | 0.42 | 12.04 | |
| 2018-12-31 | 21.21 | 0.23 | 10.97 | |
| 2018-09-30 | 18.63 | 0.10 | 10.36 | |
| 2018-06-30 | 16.32 | -0.77 | 9.46 | |
| 2018-03-31 | 14.09 | -1.41 | 8.05 | |
| 2017-12-31 | 12.13 | -2.10 | 7.39 | |
| 2017-09-30 | 10.41 | -2.22 | 6.70 | |
| 2017-06-30 | 9.10 | -1.84 | 6.08 | |
| 2017-03-31 | 8.14 | -2.07 | 6.05 | |
| 2016-12-31 | 7.75 | -1.54 | 5.64 | |
| 2016-09-30 | 7.48 | -1.60 | 1.96 | |
| 2016-06-30 | 7.70 | -1.27 | 1.49 | |
| 2016-03-31 | 7.49 | -0.84 | 1.04 | |
| 2015-12-31 | 7.22 | -0.60 | 0.63 | |
| 2015-09-30 | 7.17 | 0.05 | 0.77 | |
| 2015-06-30 | 6.98 | -0.33 | 1.07 | |
| 2015-03-31 | 6.70 | -0.37 | 1.00 | |
| 2014-12-31 | 6.50 | -1.03 | 1.26 | |
| 2014-09-30 | 6.07 | -1.13 | 1.41 | |
| 2014-06-30 | 5.62 | -0.98 | 1.23 | |
| 2014-03-31 | 5.30 | -0.80 | 0.88 | |
| 2013-12-31 | 4.68 | -0.27 | 0.57 | |
| 2013-09-30 | 3.84 | -0.36 | 3.71 | |
| 2013-06-30 | 2.92 | -0.33 | 3.01 | |
| 2013-03-31 | 2.33 | -0.38 | 2.68 | |
| 2012-12-31 | 1.99 | -0.45 | 2.14 | |
| 2012-09-30 | 1.62 | -0.58 | 0.99 | |
| 2012-06-30 | 1.36 | -1.56 | 1.15 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- OptimizeRx has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- OptimizeRx used its assets less efficiently than the US Healthcare Services industry average last year based on Return on Assets.
- OptimizeRx has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
Past performance checks
We assess OptimizeRx's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
OptimizeRx has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
OPRX Health
How is OptimizeRx's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up OptimizeRx's finances.
The net worth of a company is the difference between its assets and liabilities.
- OptimizeRx is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- OptimizeRx's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 1.3945711498126E+17x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from OptimizeRx Company Filings, last reported 2 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 19.44 | 0.65 | 10.13 |
| 2018-12-31 | 18.46 | 0.00 | 8.91 |
| 2018-09-30 | 17.20 | 0.00 | 13.52 |
| 2018-06-30 | 15.80 | 0.00 | 12.00 |
| 2018-03-31 | 6.83 | 0.00 | 4.30 |
| 2017-12-31 | 6.22 | 0.00 | 5.12 |
| 2017-09-30 | 6.05 | 0.00 | 5.01 |
| 2017-06-30 | 6.47 | 0.00 | 5.84 |
| 2017-03-31 | 7.06 | 0.00 | 6.72 |
| 2016-12-31 | 7.81 | 0.00 | 7.03 |
| 2016-09-30 | 8.04 | 0.00 | 7.57 |
| 2016-06-30 | 8.16 | 0.00 | 7.57 |
| 2016-03-31 | 8.55 | 0.00 | 7.55 |
| 2015-12-31 | 8.94 | 0.00 | 8.21 |
| 2015-09-30 | 9.24 | 0.00 | 8.17 |
| 2015-06-30 | 4.70 | 0.00 | 3.65 |
| 2015-03-31 | 4.58 | 0.00 | 3.51 |
| 2014-12-31 | 4.61 | 0.00 | 3.45 |
| 2014-09-30 | 4.85 | 0.00 | 3.26 |
| 2014-06-30 | 4.78 | 0.00 | 3.55 |
| 2014-03-31 | 4.60 | 0.00 | 4.03 |
| 2013-12-31 | 1.67 | 0.00 | 1.12 |
| 2013-09-30 | 2.07 | 0.00 | 0.49 |
| 2013-06-30 | 1.78 | 0.00 | 0.35 |
| 2013-03-31 | 1.39 | 0.00 | 0.26 |
| 2012-12-31 | 1.40 | 0.00 | 0.28 |
| 2012-09-30 | 1.33 | 0.00 | 0.28 |
| 2012-06-30 | 1.39 | 0.00 | 0.53 |
- OptimizeRx's level of debt (0%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has been reduced over the past 5 years (0% vs 0% today).
- Debt is well covered by operating cash flow (2.2246989525675E+18%, greater than 20% of total debt).
- OptimizeRx earns more interest than it pays, coverage of interest payments is not a concern.
Financial health checks
We assess OptimizeRx's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) OptimizeRx has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
OPRX Dividends
What is OptimizeRx's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
OptimizeRx
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate OptimizeRx's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate OptimizeRx's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 4 Analyst Estimates (S&P Global) | See Below |
| Global Healthcare Services Industry Average Dividend Yield | Market Cap Weighted Average of 15 Stocks | 1.1% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2011 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as OptimizeRx has not reported any payouts.
- Unable to verify if OptimizeRx's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess OptimizeRx's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can OptimizeRx afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) OptimizeRx has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
OPRX Management
CEO
| COMPENSATION | $923,138 |
| AGE | 49 |
| TENURE AS CEO | 3.3 years |
CEO Bio
Mr. William J. Febbo, also known as Will, has been the Chief Executive Officer and Director of OptimizeRx Corp since February 22, 2016. Mr. Febbo is a Founder of Plexuus, an early stage payment processing platform for medical professionals with Sunshine Act-related activities. Mr. Febbo has more than 18 years of experience in building and managing health services and financial businesses. Mr. Febbo served as Chairman and Founder of Plexus, LLC, a payment processing business for medical professionals. He was a Director of the Merriman Holdings, Inc. (“Merriman”) from April 2007 to February 2016. When Febbo sold it in 2007 to Merriman Capital, he held dual roles as COO of the bank and CEO of Digital Capital Network which he launched pioneering digital compliance & transparency in the financial industry. He joined MIT linQ as a faculty member. Hehas participated in two of these programs, IMPACT and Idea2 global. He advises several companies in the US, Spain and South America and has a passion for reviving existing businesses with disruptive technology. Prior to Merriman, He founded and ran MedPanel, LLC in 1999. He has been Treasurer of the Board of the United Nations of Greater Boston since November 2004. He holds a Bachelor of Arts in International Studies from Dickinson College, in Pennsylvania.
CEO Compensation
- Will's compensation has increased in line with OptimizeRx recently becoming profitable.
- Will's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the OptimizeRx management team in years:
- The tenure for the OptimizeRx management team is about average.
Management Team
Will Febbo
CEO & Director
$923K
49
3.3 yrs
Miriam Paramore
President
$445K
55
1.8 yrs
Doug Baker
Chief Financial Officer
$426K
61
5.1 yrs
Terry Hamilton
Senior Vice President of Sales
$512K
53
3.4 yrs
Steve Silvestro
Chief Commercial Officer
0.2 yrs
James Brooks
Consultant
$421K
49
2.4 yrs
Board of Directors Tenure
Average tenure and age of the OptimizeRx board of directors in years:
- The average tenure for the OptimizeRx board of directors is less than 3 years, this suggests a new board.
Board of Directors
Gus Halas
Chairman
$131K
67
2 yrs
Will Febbo
CEO & Director
$923K
49
Jay Pinney
Head of Medical Advisory Board
$113K
61
1.3 yrs
Lynn Vos
Independent Director
$103K
62
3.8 yrs
Jim Lang
Independent Director
$120K
53
2.4 yrs
Pat Spangler
Independent Director
$106K
62
1.3 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 07. Jun 19 | Sell | Wolverine Asset Management, LLC | Company | 09. May 19 | 15. May 19 | -5,310 | $16.05 | $-81,764 | ||
| 07. Jun 19 | Buy | Wolverine Asset Management, LLC | Company | 16. May 19 | 04. Jun 19 | 6,577 | $14.85 | $92,638 | ||
| 22. May 19 | Sell | AWM Investment Company Inc. | Company | 14. May 19 | 14. May 19 | -42,874 | $13.63 | $-583,219 | ||
| 13. May 19 | Sell | AWM Investment Company Inc. | Company | 09. May 19 | 13. May 19 | -82,126 | $13.76 | $-1,120,224 | ||
| 19. Mar 19 | Sell | AWM Investment Company Inc. | Company | 15. Mar 19 | 18. Mar 19 | -21,397 | $15.15 | $-322,108 | ||
| 20. Dec 18 | Buy | William Febbo | Individual | 19. Dec 18 | 19. Dec 18 | 2,000 | $9.94 | $19,880 | ||
| 20. Dec 18 | Buy | Miriam Paramore | Individual | 19. Dec 18 | 19. Dec 18 | 1,015 | $9.85 | $9,998 | ||
| 08. Nov 18 | Buy | William Febbo | Individual | 07. Nov 18 | 07. Nov 18 | 600 | $16.32 | $9,792 | ||
| 10. Aug 18 | Sell | Douglas Baker | Individual | 09. Aug 18 | 10. Aug 18 | -4,784 | $12.05 | $-57,468 | ||
| 28. Jun 18 | Buy | Patrick Spangler | Individual | 27. Jun 18 | 27. Jun 18 | 95 | $9.95 | $945 | ||
| 27. Jun 18 | Buy | Ellen Vos | Individual | 22. Jun 18 | 25. Jun 18 | 1,800 | $10.72 | $18,852 | ||
| 26. Jun 18 | Buy | Miriam Paramore | Individual | 22. Jun 18 | 22. Jun 18 | 100 | $10.50 | $1,050 | ||
| 25. Jun 18 | Buy | William Febbo | Individual | 22. Jun 18 | 22. Jun 18 | 1,000 | $10.50 | $10,500 | ||
Management checks
We assess OptimizeRx's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) OptimizeRx has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
OPRX News
Simply Wall St News
Is OptimizeRx Corporation's (NASDAQ:OPRX) Capital Allocation Ability Worth Your Time?
Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. … Analysts use this formula to calculate return on capital employed: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) Or for OptimizeRx: 0.058 = US$1.2m ÷ (US$25m - US$3.9m) (Based on the trailing twelve months to March 2019.) Therefore, OptimizeRx has an ROCE of 5.8%. … Due to the way ROCE is calculated, a high level of current liabilities makes a company look as though it has less capital employed, and thus can (sometimes unfairly) boost the ROCE.
Simply Wall St - – Full articleRead This Before Judging OptimizeRx Corporation's (NASDAQ:OPRX) ROE
One way to conceptualize this, is that for each $1 of shareholders' equity it has, the company made $0.022 in profit. … The formula for return on equity is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for OptimizeRx: 2.2% = US$422k ÷ US$19m (Based on the trailing twelve months to March 2019.) Most know that net profit is the total earnings after all expenses, but the concept of shareholders' equity is a little more complicated. … One simple way to determine if a company has a good return on equity is to compare it to the average for its industry.
Simply Wall St - – Full articleDo Institutions Own OptimizeRx Corporation (NASDAQ:OPRX) Shares?
The big shareholder groups in OptimizeRx Corporation (NASDAQ:OPRX) have power over the company. … Generally speaking, as a company grows, institutions will increase their ownership. … OptimizeRx is not a large company by global standards.
Simply Wall St - – Full articleDoes OptimizeRx Corporation (NASDAQ:OPRX) Have A Volatile Share Price?
Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider. … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.
Simply Wall St - – Full articleWhy I Like OptimizeRx Corporation (NASDAQ:OPRX)
I've been keeping an eye on OptimizeRx Corporation (NASDAQ:OPRX) because I'm attracted to its fundamentals. … Looking at the company as a whole, as a potential stock investment, I believe OPRX has a lot to offer. … is a company with
Simply Wall St - – Full articleThe OptimizeRx Share Price Is Up 399% And Shareholders Are Delighted
Given that OptimizeRx only made minimal earnings in the last twelve months, we'll focus on revenue to gauge its business development. … As a general rule, if the market is looking past earnings to focus on revenue, there is a hope for, or expectation of, strong growth. … The main reason for this is that fast revenue growth can be readily extrapolated into a profitable future, but stagnant revenue cannot.
Simply Wall St - – Full articleIs OptimizeRx Corporation's (NASDAQ:OPRX) CEO Paid Enough Relative To Peers?
In 2016 Will Febbo was appointed CEO of OptimizeRx Corporation (NASDAQ:OPRX). … First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Will Febbo's Compensation Compare With Similar Sized Companies?
Simply Wall St - – Full articleWhy We’re Not Keen On OptimizeRx Corporation’s (NASDAQ:OPRX) 0.005% Return On Capital
To be precise, we'll consider its Return On Capital Employed (ROCE), as that will inform our view of the quality of the business. … Understanding Return On Capital Employed (ROCE). … ROCE measures the 'return' (pre-tax profit) a company generates from capital employed in its business.
Simply Wall St - – Full articleWhen Should You Buy OptimizeRx Corporation (NASDAQ:OPRX)?
saw a decent share price growth in the teens level on the NasdaqCM over the last few months. … With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price? … Let’s examine OptimizeRx’s valuation and outlook in more detail to determine if there’s still a bargain opportunity
Simply Wall St - – Full articleCould OptimizeRx Corporation's (NASDAQ:OPRX) Investor Composition Influence The Stock Price?
Generally speaking, as a company grows, institutions will increase their ownership. … OptimizeRx is a smaller company with a market capitalization of US$114m, so it may still be flying under the radar of many institutional investors. … Our analysis of the ownership of the company, below, shows that.
Simply Wall St - – Full articleOPRX Company Info
Description
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company’s cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems to search, print, or electronically dispense directly to patients, as well as for a network of pharmacies; and Brand and Clinical Messaging that includes various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages targeted by specialty, diagnostic code, and other criteria. The company’s products and applications also comprise brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing new eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. It also operates Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence, care coordination, and patient engagement; and HIPAA-compliant, an automated and mobile messaging platform that allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. OptimizeRx Corporation is based in Rochester, Michigan.
Details
| Name: | OptimizeRx Corporation |
| OPRX | |
| Exchange: | NasdaqCM |
| Founded: | |
| $197,035,168 | |
| 13,817,333 | |
| Website: | http://www.optimizerx.com |
| Address: |
OptimizeRx Corporation 400 Water Street, Suite 200, Rochester, Michigan, 48307, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqCM | OPRX | Common Shares | Nasdaq Capital Market | US | USD | 23. Jun 2005 |
Number of employees
Current staff
Industry
| Health Care Technology | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/06/16 00:15 |
| End of day share price update: | 2019/06/14 00:00 |
| Last estimates confirmation: | 2019/05/09 |
| Last earnings filing: | 2019/05/08 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
